Craig Wierum, MD
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1609867233
Payments from drug & device makers
Across 2,556 payments — averaging $657.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$799K
- Novo Nordisk$432K
- Novo Nordisk AS$368K
- Boehringer Ingelheim$63K
- Corcept Therapeutics$4K
- Mannkind Corporation$2K
- plus $12K from 34 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1,133 | $798,937 |
| Novo Nordisk | 443 | $432,240 |
| Novo Nordisk AS | 309 | $367,590 |
| Boehringer Ingelheim | 133 | $63,250 |
| Corcept Therapeutics | 15 | $4,248 |
| Mannkind Corporation | 150 | $2,015 |
| AbbVie | 12 | $1,876 |
| Amgen | 63 | $1,863 |
| Abbott | 104 | $1,549 |
| Insulet Corporation | 25 | $871 |
| Cequr Corporation | 3 | $705 |
| Medtronic(2 entities) | 22 | $649 |
| Tandem Diabetes Care, Inc. | 12 | $553 |
| BETA Bionics, Inc. | 20 | $517 |
| Xeris Pharmaceuticals, Inc. | 23 | $490 |
| Sanofi-aventis U.S. LLC | 14 | $487 |
| AstraZeneca | 9 | $473 |
| Dexcom, Inc. | 10 | $320 |
| Ascendis Pharma Endocrinology Inc | 11 | $211 |
| Amneal Pharmaceuticals LLC | 11 | $211 |
| Novartis | 2 | $179 |
| Valeritas, Inc. | 2 | $137 |
| Bayer | 1 | $130 |
| Companion Medical, Inc. | 1 | $125 |
| Radius Health, Inc. | 1 | $118 |
| Zealand Pharma US, Inc. | 1 | $117 |
| Eisai Inc. | 1 | $109 |
| IBSA Pharma Inc. | 5 | $97 |
| Ascensia Diabetes Care US Inc. | 3 | $70 |
| Amphastar Pharmaceuticals, Inc. | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $58 |
| Sequel Med Tech, LLC | 2 | $57 |
| Nevro Corp. | 2 | $37 |
| Bigfoot Biomedical Inc | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Senseonics, Incorporated | 1 | $24 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| GSK | 1 | $21 |
| Sanofi | 1 | $20 |
| Halozyme Inc | 1 | $19 |
How this compares
$1,680,509 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Nashville
- Stephen SharpNashville$25.9M
- Kathryn DahirNashville$11M
- Terri JerkinsNashville$1.2M
- Shichun BaoNashville$735K
- Michael MayNashville$689K
- Michael CarlsonNashville$381K
- Rodney SnowNashville$188K
- Kevin NiswenderNashville$100K
- Howard BaumNashville$81K
- Annis MarneyNashville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.